Synapse - Works

Results (5608)

Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets

Meeting Abstract

Bandini, M.; Pederzoli, F.; Madison, R.; Briganti, A.; Plimack, E. R.; Ross, J. S.; Niegisch, G.; Yu, E. Y.; Bamias, A.; Agarwal, N.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC)

Meeting Abstract

Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S.; Slovin, S. F.; Blinder, V. S.; Comen, E. A.; Danila, D. C.; Hoffman, D. M. J.; Kang, S.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Targeting checkpoint kinases in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors

Meeting Abstract

Atiq, M. O.; Chakraborty, G.; Nandakumar, S.; Mazzu, Y. Z.; Stopsack, K. H.; Jehane, L. E.; Yoshikawa, Y.; Khan, N.; Lee, G. S. M.; Kantoff, P. W.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG)

Meeting Abstract

Abu Zaid, M. I.; Milano, M. T.; Dinh, P. C.; Fossa, S.; Yang, H.; Feldman, D. R.; Travis, L. B.; Fung, C.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2

Meeting Abstract

Abida, W.; Bryce, A. H.; Vogelzang, N. J.; Amato, R. J.; Percent, I. J.; Shapiro, J. D.; McDermott, R. S.; Hussain, A.; Patnaik, A.; Petrylak, D. P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma

Meeting Abstract

Tannir, N. M.; Agarwal, N.; Dawson, N. A.; Motzer, R. J.; Jacobs, C. M.; Choueiri, T. K.; Hrom, J. S.; Geynisman, D. M.; Davis, N. B.; Figlin, R. A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Metacure: Multi-arm multimodality therapy for very high risk localized and low volume metastatic prostatic adenocarcinoma

Meeting Abstract

Teo, M. Y.; Taplin, M. E.; Eastham, J. A.; Benoliel, H.; Kibel, A. S.; McBride, S. M.; Nguyen, P. L.; Gopalan, A.; Lis, R.; Scher, H. I.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT)

Meeting Abstract

Wong, N. C.; Dason, S.; Dean, L. W.; Isharwal, S.; Donoghue, M.; Jia, L.; Joseph, G.; Tap, W. D.; Funt, S. A.; McHugh, D. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED

Meeting Abstract

Vogelzang, N. J.; Kantoff, P. W.; Scholz, M. C.; Vacirca, J. L.; Dakhil, S. R.; Goel, S.; Harmon, M.; Tang, H.; Brown, B.; Armstrong, A. J.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors

Meeting Abstract

Sonpavde, G.; Hennessy, D.; Manitz, J.; Niegisch, G.; Powles, T.; Rosenberg, J. E.; Bajorin, D. F.; Apolo, A. B.; Pond, G. R.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save